A new systematic review and meta-analysis indicates that there were no significant differences in venous thromboembolism (VTE) occurrence in patients with COVID-19 compared to those without. “Many studies confirmed an association between COVID-19 and VTE,” the authors wrote in Vascular Pharmacology. Whether the risk of VTE significantly differed between COVID-19 cohorts and non-COVID-19 cohorts with similar disease severity remains unknown.” According to the study results, the cumulative RR estimate for VTE among COVID-19 patients was 1.18 (95% CI, 0.79 to 1.77; P=0.42) when compared to those without COVID-19. There were also no observed differences in pulmonary embolism only (RR=1.25; 95% CI, 0.77 to 2.03) and deep vein thrombosis only (RR=0.92; 95% CI, 0.52 to 1.65).
More than 20% of stable outpatients with coronary artery disease (CAD) reported experiencing angina at least once per month, according to a study published in JAMA Network Open. This study involved telephone-based administration of the Seattle Angina Questionnaire–7 (SAQ-7) between February and July 2017. The investigators identified and contacted 4,139 patients aged ≥30 years with established CAD receiving primary care through an integrated primary care network. In total, 1,612 patients (38.9%) responded to the survey. Compared to non-respondents, patients who responded to the survey tended to be younger (mean age, 73.2 vs. 71.8 years), were more likely to speak Spanish (5.3% vs. 9.1%), and were more likely to have Medicaid insurance (4.2% vs. 5.2%).
A new study shows that among patients with ischemic stroke, the use of implantable electrocardiographic monitoring is appreciably more effective at detecting atrial fibrillation (AFib) compared to prolonged external monitoring. Researchers assessed 300 patients (median age, 64, 40.3% women) who were randomized (1:1) to receive either implantable electrocardiographic monitoring for 12 months (n=150), or prolonged electrocardiographic monitoring for 30 days following an ischemic stroke (n=150). The primary endpoint was defined as the development of definite AFib or highly probable AFib. According to the results, the primary outcome was observed in 15.3% of patients in the implantable loop recorder group compared to only 4.7% of patients in the external loop recorder group (between-group difference, 10.7% [95% CI, 4.0%-17.3%]; risk ratio, 3.29 [95% CI, 1.45-7.42]; P=0.003).
Patients presenting with atypical symptoms of myocardial infarction (MI) when calling for help are less likely to receive an emergency dispatch and have increased mortality, according to a study published online in the European Heart Journal: Acute Cardiovascular Care. A total of 4,880 emergency and 3,456 nonemergency calls from patients with MI were identified. The primary symptom was categorized as chest pain, atypical symptoms, unconsciousness, noninformative symptoms, and no recorded symptoms. The researchers found that the most common symptoms were chest pain and breathing problems (5,219 and 556 patients, respectively). Among patients with chest pain, 95 and 76 percent of emergency calls and nonemergency calls, respectively, received emergency dispatch, and mortality was 5 and 3 percent, respectively.